Guajacuran

Guajacuran is a pharmaceutical product containing the expectorant active ingredient guaifenesin, supplied in an intravenous formulation for use in the European Union market. It is classified as an expectorant within the respiratory system therapeutic class and is identified by ATC code R05CA01. The medication works by increasing the volume and decreasing the viscosity of respiratory secretions, thereby aiding the clearance of mucus from the airways.

Guajacuran is indicated for the symptomatic relief of chest congestion and to facilitate the expectoration of mucus in patients with respiratory conditions.

- Relief of chest congestion associated with acute bronchitis or upper respiratory infections. - Facilitation of mucus clearance in chronic obstructive pulmonary disease (COPD) exacerbations. - Adjunctive therapy for patients with cystic fibrosis experiencing thick secretions. - Supportive treatment during postoperative pulmonary care to reduce retained secretions. - Use in clinical settings where rapid mucolytic action via intravenous administration is preferred.

The safety profile of Guajacuran reflects the typical effects observed with intravenous guaifenesin, ranging from mild, frequently reported reactions to rare, more serious events.

Common: - Nausea or mild gastrointestinal discomfort occurring shortly after infusion. - Headache or dizziness that resolves without intervention. - Transient flushing, warmth, or mild irritation at the intravenous site. - Increased production of respiratory secretions leading to a temporary, productive cough.

Serious: - Allergic skin reactions such as rash, itching, or urticaria. - Severe bronchospasm or sudden difficulty breathing requiring medical attention. - Significant hypotension or rapid heart rate (tachycardia) during or after administration. - Anaphylactic reaction, a rare but potentially life‑threatening event.

When using Guajacuran, healthcare professionals should consider several precautionary measures to ensure safe administration and minimize risk.

- Assess patient history for hypersensitivity to guaifenesin or any formulation components. - Use caution in individuals with cardiovascular instability or uncontrolled hypertension. - Monitor vital signs, especially blood pressure and heart rate, during and after infusion. - Adjust dosage or infusion rate in patients with renal or hepatic impairment. - Avoid concurrent use with other mucolytic agents unless clinically justified. - Ensure proper intravenous access and aseptic technique to prevent infection.

Guajacuran may interact with certain medications; awareness of these interactions helps guide safe co‑administration.

Avoid: - Concurrent use with other potent mucolytics that may increase secretions excessively. - Co‑administration with drugs known to cause severe hypotension, such as certain antihypertensives.

Use with caution: - Beta‑agonist bronchodilators, as additive effects on airway tone may occur. - Anticoagulants, because changes in blood pressure could affect bleeding risk. - Sedatives or central nervous system depressants, which may enhance dizziness or drowsiness.